<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00581828</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0159</org_study_id>
    <secondary_id>05-1235-02</secondary_id>
    <nct_id>NCT00581828</nct_id>
  </id_info>
  <brief_title>Does Treatment of Hypovitaminosis D Increase Calcium Absorption?</brief_title>
  <official_title>Does Treatment of Hypovitaminosis D Increase Calcium Absorption?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to perform a one-year study designed to assess whether treatment of
      hypovitaminosis D increases intestinal absorption of calcium, subsequent retention of calcium
      within bone, decreases bone turnover, and favorably impacts upon skeletal muscle mass,
      functional status, measures of physical function and quality of life. I hypothesize that
      treatment of hypovitaminosis D results in improved intestinal calcium absorption, greater
      retention of calcium within the bone reservoir and improved physical function, quality of
      life and muscle mass.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postmenopausal women with vitamin D insufficiency will participate in this one-year study. We
      will study the change in intestinal calcium absorption from baseline (vitamin D
      insufficiency) to follow up (vitamin D repletion and whether increased absorption results in
      subsequent increased retention of calcium within bone over the one-year interval as measured
      by bone densitometry. We will also study the effect of vitamin D repletion upon whole body
      muscle mass, quality of life and physical function.

      A review of medical records and a screening visit will determine eligibility. Eligible and
      consenting subjects will present to the GCRC in the early morning and following baseline
      labs, will consume breakfast with a glass of orange juice enriched with a stable calcium
      isotope, and will receive 3 mg of another stable calcium isotope by intravenous injection.
      Over the next eight hours, blood will be taken a total of 9 more times and over the first 24
      hours, all urine and stool will be collected for measurement of its calcium content.

      Subsequently for the next five days, women will collect three urine specimens daily. Women
      will then receive vitamin D to treat vitamin D deficiency. Once vitamin D repletion is
      accomplished, all women will repeat their 24-hour visit and subsequent five-day urine
      collections. Women will maintain vitamin D repletion by taking a twice monthly tablet (50,000
      IU) of vitamin D2. To confirm vitamin D repletion and safety over the full one year study,
      additional study visits will occur at 3, 6 and 12 months.

      A bone density test at screening and twelve months will allow us to assess the effect of
      vitamin D repletion on whole body bone mass and skeletal mass. At each GCRC stay, 3, 6 and 12
      months, women will complete questionnaires regarding quality of life and functional status
      and will perform the Timed Up and Go Test. Because we wish to maintain and confirm constant
      calcium intake throughout the one- year study, women will complete a calcium questionnaire at
      baseline, 3, 6 and 12 months.

      With each subject's consent, we will collect one tube of blood and isolate its DNA. When
      sufficient knowledge is available regarding the pathophysiologic mechanisms whereby genetic
      polymorphisms impact calcium homeostasis, we will test for such DNA polymorphisms and relate
      genetic information with other data collected on calcium homeostasis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Intestinal Calcium Absorption From Baseline to One Month</measure>
    <time_frame>1 month</time_frame>
    <description>percent and true fractional calcium absorption</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Osteopenia</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Hypoparathyroidism</condition>
  <condition>Hypercalciuria</condition>
  <condition>Hypercalcemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received vitamin D (50,000 IU daily for 15 days) and maintenance dose vitamin D (50,000 IU twice monthly for 10 months).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>50,000 IU po qd for 15 days and 50,000 IU po twice month for 10 months (until final study visit at one year)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Vitamin D2</other_name>
    <other_name>Ergocalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women at least five years past onset of menopause, defined as date of last menses

          -  serum 25(OH)D 16-24 ng/ml by reverse phase HPLC

          -  calcium intake &lt; or = 1,100 mg daily

        Exclusion Criteria:

          -  Intake of &gt;1,100 mg of calcium per day through the combination of diet and supplements

          -  Hypercalcemia (baseline serum calcium above the normal reference range)

          -  Nephrolithiasis, documented in the medical record or by patient report

          -  Inflammatory bowel disease, malabsorption, chronic diarrhea, or use of antibiotics
             within the past month

          -  Creatinine &gt;2.0 mg/dL

          -  Hypercalciuria (baseline urine calcium: creatinine ratio &gt;0.25)

          -  Current use of medications known to interfere with vitamin D and/or calcium
             metabolism, including oral steroids or anticonvulsants

          -  Ongoing or recent (past six months) use of bisphosphonates, estrogen compounds,
             calcitonin or teriparatide, as these compounds may independently affect retention of
             calcium within bone

          -  Diagnosis of, or evidence for, osteomalacia, manifest by serum 25(OH)D &lt; 16 ng/ml or
             the presence of at least two of the following blood tests: low calcium, low
             phosphorus, or elevated alkaline phosphatase (23).

          -  Prior adult clinical fragility fracture or baseline T-score below -3.0 at the lumbar
             spine or femur
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen E Hansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hansen KE, Jones AN, Lindstrom MJ, Davis LA, Engelke JA, Shafer MM. Vitamin D insufficiency: disease or no disease? J Bone Miner Res. 2008 Jul;23(7):1052-60. doi: 10.1359/jbmr.080230.</citation>
    <PMID>18302509</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2007</study_first_posted>
  <results_first_submitted>July 6, 2012</results_first_submitted>
  <results_first_submitted_qc>September 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 14, 2012</results_first_posted>
  <last_update_submitted>September 13, 2012</last_update_submitted>
  <last_update_submitted_qc>September 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Calcium Absorption</keyword>
  <keyword>Intestinal Absorption of Calcium</keyword>
  <keyword>Fractional Calcium Absorption</keyword>
  <keyword>Stable Calcium Isotopes</keyword>
  <keyword>Hypovitaminosis D</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Bone Mineral Density</keyword>
  <keyword>Physical Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Hypoparathyroidism</mesh_term>
    <mesh_term>Avitaminosis</mesh_term>
    <mesh_term>Hypercalcemia</mesh_term>
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Hypercalciuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D</title>
          <description>Subjects received vitamin D (50,000 IU daily for 15 days) and maintenance dose vitamin D (50,000 IU twice monthly for 10 months).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D</title>
          <description>Subjects received vitamin D (50,000 IU daily for 15 days) and maintenance dose vitamin D (50,000 IU twice monthly for 10 months).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Intestinal Calcium Absorption From Baseline to One Month</title>
        <description>percent and true fractional calcium absorption</description>
        <time_frame>1 month</time_frame>
        <population>One subject's urine sample was mishandled, leaving 18 subjects with complete data for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Subjects received vitamin D (50,000 IU daily for 15 days) and maintenance dose vitamin D (50,000 IU twice monthly for 10 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Intestinal Calcium Absorption From Baseline to One Month</title>
          <description>percent and true fractional calcium absorption</description>
          <population>One subject's urine sample was mishandled, leaving 18 subjects with complete data for analysis.</population>
          <units>percent calcium absorption</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D</title>
          <description>Subjects received vitamin D (50,000 IU daily for 15 days) and maintenance dose vitamin D (50,000 IU twice monthly for 10 months).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Karen Hansen</name_or_title>
      <organization>University of Wisconsin</organization>
      <phone>608-263-3457</phone>
      <email>keh@medicine.wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

